Mycotopia Therapies
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Mycotopia Therapies generated cash of -$106,765, which is more than the previous year. Cash used in financing activities reached the amount of $0 last year. Net change in cash is therefore -$106,765.
Cash Flow
| 2017 | 232.82K | 0 | 4.83K |
|---|---|---|---|
| 2018 | -68.53K | 0 | 0 |
| 2019 | 98.66K | -1K | 0 |
| 2020 | -302.80K | -349K | 125K |
| 2021 | -235.48K | -2.74K | 1.39M |
| 2022 | -656.62K | 0 | -225K |
| 2023 | -106.76K | 0 | 0 |
TPIA Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 385.89K | 1.26M | 110.74K | 709.16K | 611.49K | 680.03K | 442.37K |
Operating activities | |||||||
Net income | -1.18M | -2.75M | -2.82M | -242.20K | 4.80K | 61.20K | 129.81K |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 61.21K | 1.00K | 249 | 548 | 323 | 672 | 897 |
Stock-based compensation expense | 635 | 1.02M | 4.31M | 44.60K | 0 | 0 | 0 |
| Deferred income tax benefit | 635 | 1.02M | 4.31M | 44.60K | 0 | 0 | 0 |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 0 | 0 | 0 | 9.61K | 0 | 0 | -51.51K |
Inventories | 0 | 0 | 0 | -9.61K | 0 | 0 | 0 |
Accounts payable | 160.10K | 465.70K | 170.81K | -54.81K | 52.72K | 3.23K | 128.67K |
Cash generated by operating activities | -106.76K | -656.62K | -235.48K | -302.80K | 98.66K | -68.53K | 232.82K |
Investing activities | |||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | 0 | -2.74K | 0 | 0 | 0 | 0 |
Acquisitions Net | 0 | 0 | 0 | -350K | 0 | 0 | 0 |
Cash generated by investing activities | 0 | 0 | -2.74K | -349K | -1K | 0 | 0 |
Financing activities | |||||||
Common Stock Issued | 0 | 150K | 0 | 0 | 0 | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | -375K | -1.39M | -125K | 0 | 0 | 0 |
Cash used in financing activities | 0 | -225K | 1.39M | 125K | 0 | 0 | 4.83K |
Net Change In Cash | -106.76K | -881.62K | 1.15M | -651.80K | 97.66K | -68.53K | 237.65K |
Cash at end of period | 279.13K | 385.89K | 1.26M | 57.35K | 709.16K | 611.49K | 680.03K |
| Data source | Data source | Data source | Data source | Data source |